Stock Monitor: Global Cord Blood Post Earnings Reporting
LONDON, UK / ACCESSWIRE / July 17, 2018 / If you want access to our free research report on Advaxis, Inc. (NASDAQ: ADXS), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ADXS as the Company's latest news hit the wire. On July 11, 2018, the Company announced that the US Food and Drug Administration (FDA) has lifted the clinical hold on its Investigational New Drug (IND) application for its Phase-1/2 study of axalimogene filolisbac (AXAL). The drug is used in combination with durvalumab for the treatment of patients with advanced, recurrent, or refractory cervical cancer and HPV-associated head and neck cancer. Register today and get access to over 1,000 Free Research Reports by joining our site below:
Active-Investors.com is currently working on the research report for Global Cord Blood Corporation (NYSE: CO), which also belongs to the Healthcare sector as the Company Advaxis. Do not miss out and become a member today for free to access this upcoming report at:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Advaxis most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
The clinical hold was issued on March 09, 2018, after a patient's death that occurred on February 27, 2018, post-dosing, involving acute respiratory failure after nine months of combination therapy.
About Axalimogene Filolisbac
Axalimogene filolisbac is a targeted Listeria monocytogenes (Lm)-based immunotherapy that attacks HPV-associated cancers by changing a live strain of Lm bacteria to generate cancer-fighting T cells against cancer antigens, while neutralizing the tumor's natural protections that guard the tumor microenvironment from immunologic attack.
In a Phase-2 trial evaluating axalimogene filolisbac for the treatment of persistent or recurrent metastatic carcinoma of the cervix (PRmCC), the drug candidate showed a 12-month overall survival rate of 38% in 50 patients. This was a 52% improvement over the 12-month overall survival rate that was expected in the trial's patient population based on prognostic factors.
Axalimogene filolisbac has received a Fast Track designation for adjuvant therapy for high-risk locally advanced cervical cancer (HRLACC) and a Special Protocol Assessment for the Phase-3 AIM2CERV trial in HRLACC patients. The immunotherapy has also received an Orphan Drug designation in three clinical indications.
Advaxis stated that new guidelines for the early detection and treatment of such rare events have been agreed with the FDA and will be implemented for this combination study. The enrolment and dosing in all other Advaxis and durvalumab clinical programs were not affected by the clinical hold.
Upon the lifting of the clinical hold by the FDA, Kenneth A. Berlin, President and Chief Executive Officer (CEO) of Advaxis, said:
"We are pleased to have resolved this issue with the FDA and will implement these guidelines across Advaxis' portfolio as needed, to ensure patient safety. We remain confident in the safety of axalimogene filolisbac based on our experience in treating approximately 400 patients and more than 1,200 doses across multiple trials in HPV-associated cancers."
About Advaxis, Inc.
Advaxis is a late-stage biotechnology organization which is focused on the discovery, development, and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T cells to eliminate tumors.
Stock Performance Snapshot
July 16, 2018 - At Monday's closing bell, Advaxis' stock rose 7.46%, ending the trading session at $1.44.
Volume traded for the day: 2.08 million shares, which was above the 3-month average volume of 736.65 thousand shares.
After yesterday's close, Advaxis' market cap was at $75.23 million.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.